James C. Yager

Array ( [id] => 17913255 [patent_doc_number] => 20220315650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/683888 [patent_app_country] => US [patent_app_date] => 2022-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17683888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18199491 [patent_doc_number] => 20230053010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => Methods of Treating Glioblastoma [patent_app_type] => utility [patent_app_number] => 17/682781 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17682781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17687739 [patent_doc_number] => 20220195031 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => AMINO ACID SEQUENCES DIRECTED AGAINST IL-17A, IL-17F AND/OR IL-17A/F AND POLYPEPTIDES COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 17/679675 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 115044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640657 [patent_doc_number] => 20220168395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => COMBINED PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/677589 [patent_app_country] => US [patent_app_date] => 2022-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17677589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790570 [patent_doc_number] => 20220249661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Pharmaceutical composition for preventing or treating inflammatory bowel disease comprising Tumor necrosis factor alpha inhibitor and Prostaglandin E2 [patent_app_type] => utility [patent_app_number] => 17/667885 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672710 [patent_doc_number] => 20220185877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => ANTIBODY HEAVY CHAIN CONSTANT DOMAINS [patent_app_type] => utility [patent_app_number] => 17/570954 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17570954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213605 [patent_doc_number] => 12410247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Polynucleotides encoding antibodies that specifically bind to human IL-15 [patent_app_type] => utility [patent_app_number] => 17/647082 [patent_app_country] => US [patent_app_date] => 2022-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 62 [patent_no_of_words] => 20142 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17647082 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657103 [patent_doc_number] => 20220177568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => TREATMENT OF SKIN LESIONS AND PRURITUS IN PRURIGO NODULARIS PATIENTS [patent_app_type] => utility [patent_app_number] => 17/555997 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12936 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17555997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17685942 [patent_doc_number] => 20220193234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/545894 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929836 [patent_doc_number] => 20220324961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ALLERGY THERAPY [patent_app_type] => utility [patent_app_number] => 17/541854 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541854 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17807465 [patent_doc_number] => 20220259300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => VACCINE COMPOSITION COMPRISING A MUTANT OF HUMAN INTERLEUKIN-15 [patent_app_type] => utility [patent_app_number] => 17/531914 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4888 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657099 [patent_doc_number] => 20220177564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP [patent_app_type] => utility [patent_app_number] => 17/530727 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20402279 [patent_doc_number] => 12492248 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP [patent_app_type] => utility [patent_app_number] => 17/530850 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 36471 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657100 [patent_doc_number] => 20220177565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP [patent_app_type] => utility [patent_app_number] => 17/530800 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17578797 [patent_doc_number] => 20220135652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/522320 [patent_app_country] => US [patent_app_date] => 2021-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8852 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642001 [patent_doc_number] => 20220169739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHODS FOR TREATING ASTHMA IN PEDIATRIC SUBJECTS BY ADMINISTERING AN IL-4R ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/493101 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146198 [patent_doc_number] => 20230020055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE [patent_app_type] => utility [patent_app_number] => 17/473710 [patent_app_country] => US [patent_app_date] => 2021-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17428383 [patent_doc_number] => 20220056091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/406847 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -144 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770893 [patent_doc_number] => 20230365696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => IFNGR1 BINDING MOLECULES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/019081 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597298 [patent_doc_number] => 20230272093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => IL12RB1-BINDING MOLECULES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/017282 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017282 [rel_patent_id] =>[rel_patent_doc_number] =>)